There are 3484 resources available
230P - Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
Presenter: Yohann Loriot
Session: Poster session 01
231P - Time to deterioration of quality of life as a surrogate of OS: A trial-level surrogacy analysis
Presenter: Adel Shahnam
Session: Poster session 01
2380P - Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
Presenter: Nicolas Sayegh
Session: Poster session 24
2381P - Perceived unmet needs and challenges faced by patients with advanced bladder cancer (aBC) and their caregivers: Results of a social media listening (SML) study conducted in 5 European countries
Presenter: Stephane Schuck
Session: Poster session 24
2382P - EBANO study: Clinical characteristics, treatment patterns and survival results in patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in northern Spain
Presenter: Ricardo Fernandez-Rodriguez
Session: Poster session 24
2383P - Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Presenter: Faith Jawdat
Session: Poster session 24
2384P - Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study
Presenter: Eojin Kim
Session: Poster session 24
2385P - Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study
Presenter: Chantal Stockem
Session: Poster session 24
2386P - Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 24
2387P - Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Presenter: Kenneth Carson
Session: Poster session 24